Your browser doesn't support javascript.
loading
Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis.
Kanagal-Shamanna, Rashmi; Montalban-Bravo, Guillermo; Katsonis, Panagiotis; Sasaki, Koji; Class, Caleb A; Jabbour, Elias; Sallman, David; Hunter, Anthony Michael; Benton, Christopher; Chien, Kelly S; Luthra, Rajyalakshmi; Bueso-Ramos, Carlos E; Kadia, Tapan; Andreeff, Michael; Komrokji, Rami S; Al Ali, Najla H; Short, Nicholas; Daver, Naval; Routbort, Mark J; Khoury, Joseph D; Patel, Keyur; Ganan-Gomez, Irene; Wei, Yue; Borthakur, Gautam; Ravandi, Farhad; Do, Kim-Anh; Soltysiak, Kelly A; Lichtarge, Olivier; Medeiros, L Jeffrey; Kantarjian, Hagop; Garcia-Manero, Guillermo.
Afiliação
  • Kanagal-Shamanna R; Department of Hematopathology and Molecular Diagnostics, Division of Pathology and Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. RKanagal@mdanderson.org.
  • Montalban-Bravo G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Katsonis P; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, United States.
  • Sasaki K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Class CA; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Jabbour E; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Sallman D; Malignant Hematology Department, H. Lee Moffitt Cancer Center, Tampa, FL, United States.
  • Hunter AM; Malignant Hematology Department, H. Lee Moffitt Cancer Center, Tampa, FL, United States.
  • Benton C; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Chien KS; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Luthra R; Department of Hematopathology and Molecular Diagnostics, Division of Pathology and Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Bueso-Ramos CE; Department of Hematopathology and Molecular Diagnostics, Division of Pathology and Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Kadia T; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Andreeff M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Komrokji RS; Malignant Hematology Department, H. Lee Moffitt Cancer Center, Tampa, FL, United States.
  • Al Ali NH; Malignant Hematology Department, H. Lee Moffitt Cancer Center, Tampa, FL, United States.
  • Short N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Daver N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Routbort MJ; Department of Hematopathology and Molecular Diagnostics, Division of Pathology and Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Khoury JD; Department of Hematopathology and Molecular Diagnostics, Division of Pathology and Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Patel K; Department of Hematopathology and Molecular Diagnostics, Division of Pathology and Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Ganan-Gomez I; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Wei Y; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Do KA; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Soltysiak KA; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Lichtarge O; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, United States.
  • Medeiros LJ; Department of Hematopathology and Molecular Diagnostics, Division of Pathology and Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Kantarjian H; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Blood Cancer J ; 11(3): 52, 2021 03 06.
Article em En | MEDLINE | ID: mdl-33677472
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndromes Mielodisplásicas / Proteína Supressora de Tumor p53 Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndromes Mielodisplásicas / Proteína Supressora de Tumor p53 Idioma: En Ano de publicação: 2021 Tipo de documento: Article